Component

Enalapril

Independently recorded substance, clinical endpoint or assay readout. Claims retain study-specific population and measurement context.

2 recorded relationships. Experimental role, claim status and evidence remain attached to each record.

Read recorded mechanisms Open recursive mind map

How nutrients influence it

Every nutrient with a recorded effect on this component, credited to the nutrient that acted rather than the chapter that recorded it. Open a nutrient to see the findings and the conditions they were measured under.

How nutrients reach it in more than one step

Chains of two or more recorded steps that end here, grouped by the nutrient they start from. Each step is a separate finding, so a chain is a route a mechanism could take, not proof that it does.

Tracing routes…

What it does

Every recorded relationship this component is part of, grouped by its role. Plain wording comes first; the technical statement follows.

Recorded relationships

Where it participates (unsigned role)

  1. First stroke occurred in 2.7% with enalapril–folic acid versus 3.4% with enalapril alone (HR 0.79; 95% CI 0.68–0.93).

    Folic acid → Stroke incidence source_derived_draftungraded
    Experimental context and source evidence
    experimental_model
    Double-blind randomized CSPPT: 20702 Chinese adults with hypertension and no previous stroke or myocardial infarction, stratified by MTHFR C677T genotype.
    exposure
    Enalapril 10 mg plus folic acid 0.8 mg/day versus enalapril alone; median 4.5 years.
    limitations
    Not a trial in all populations or secondary prevention; no proof of a single homocysteine-mediated mechanism.
    nutrient_topic
    Folate and folic acid research collection; topical membership is not evidence of a direct dietary effect. · Folate (vitamin B9)
    organism
    Homo sapiens
    plain_language
    Adding folic acid improved the first-stroke endpoint in this particular hypertensive population.
    primary_references
    [fol-csppt2015] Efficacy of folic acid therapy in primary prevention of stroke among adults with hypertension in China: the CSPPT randomized clinical trial (2015). https://pubmed.ncbi.nlm.nih.gov/25771069/ DOI: 10.1001/jama.2015.2274
    tissue_or_cell_type
    Human blood or whole-person clinical endpoints

    Folate and folic acid: mechanisms, deficiency and nutrient interactions (2026-09-17) · lines 1593–1603

    AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text. · supports · Double-blind randomized CSPPT: 20702 Chinese adults with hypertension and no previous stroke or myocardial infarction, stratified by MTHFR C677T genotype. · source_derived_draft · unverified_draft

    ### fol-csppt-first-stroke First stroke occurred in 2.7% with enalapril–folic acid versus 3.4% with enalapril alone (HR 0.79; 95% CI 0.68–0.93). Condition category: normal nutrient_topic: Folate and folic acid research collection; topical membership is not evidence of a direct dietary effect. plain_language: Adding folic acid improved the first-stroke endpoint in this particular hypertensive population. organism: Homo sapiens tissue_or_cell_type: Human blood or whole-person clinical endpoints experimental_model: Double-blind randomized CSPPT: 20702 Chinese adults with hypertension and no previous stroke or myocardial infarction, stratified by MTHFR C677T genotype. limitations: Not a trial in all populations or secondary prevention; no proof of a single homocysteine-mediated mechanism. exposure: Enalapril 10 mg plus folic acid 0.8 mg/day versus enalapril alone; median 4.5 years. [fol-csppt2015] Efficacy of folic acid therapy in primary prevention of stroke among adults with hypertension in China: the CSPPT randomized clinical trial (2015). https://pubmed.ncbi.nlm.nih.gov/25771069/ DOI: 10.1001/jama.2015.2274
    Complete structured claim and evidence

  2. First ischemic stroke was lower with combined treatment (HR 0.76; 95% CI 0.64–0.91); hemorrhagic stroke, MI and all-cause death did not differ significantly.

    Folic acid → Ischemic stroke incidence source_derived_draftungraded
    Experimental context and source evidence
    experimental_model
    Double-blind randomized CSPPT: 20702 Chinese adults with hypertension and no previous stroke or myocardial infarction, stratified by MTHFR C677T genotype.
    exposure
    Enalapril 10 mg plus folic acid 0.8 mg/day versus enalapril alone; median 4.5 years.
    limitations
    Secondary endpoints, event frequency and confidence intervals matter; null results do not prove identical risks.
    nutrient_topic
    Folate and folic acid research collection; topical membership is not evidence of a direct dietary effect. · Folate (vitamin B9)
    organism
    Homo sapiens
    plain_language
    The benefit was endpoint-specific, rather than a uniform reduction in every vascular event.
    primary_references
    [fol-csppt2015] Efficacy of folic acid therapy in primary prevention of stroke among adults with hypertension in China: the CSPPT randomized clinical trial (2015). https://pubmed.ncbi.nlm.nih.gov/25771069/ DOI: 10.1001/jama.2015.2274
    tissue_or_cell_type
    Human blood or whole-person clinical endpoints

    Folate and folic acid: mechanisms, deficiency and nutrient interactions (2026-09-17) · lines 1605–1615

    AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text. · supports · Double-blind randomized CSPPT: 20702 Chinese adults with hypertension and no previous stroke or myocardial infarction, stratified by MTHFR C677T genotype. · source_derived_draft · unverified_draft

    ### fol-csppt-ischemic-stroke First ischemic stroke was lower with combined treatment (HR 0.76; 95% CI 0.64–0.91); hemorrhagic stroke, MI and all-cause death did not differ significantly. Condition category: normal nutrient_topic: Folate and folic acid research collection; topical membership is not evidence of a direct dietary effect. plain_language: The benefit was endpoint-specific, rather than a uniform reduction in every vascular event. organism: Homo sapiens tissue_or_cell_type: Human blood or whole-person clinical endpoints experimental_model: Double-blind randomized CSPPT: 20702 Chinese adults with hypertension and no previous stroke or myocardial infarction, stratified by MTHFR C677T genotype. limitations: Secondary endpoints, event frequency and confidence intervals matter; null results do not prove identical risks. exposure: Enalapril 10 mg plus folic acid 0.8 mg/day versus enalapril alone; median 4.5 years. [fol-csppt2015] Efficacy of folic acid therapy in primary prevention of stroke among adults with hypertension in China: the CSPPT randomized clinical trial (2015). https://pubmed.ncbi.nlm.nih.gov/25771069/ DOI: 10.1001/jama.2015.2274
    Complete structured claim and evidence

In the sources

Preserved passages that mention this component, quoted exactly. Open one to read it in context.

    This is a research prototype built from draft material. It is not medical advice, and its statements still await verification against the original studies.

    Evidence, AI assistance and curation standards